IBC Legal is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

20 - 21 June 2017
Millennium Gloucester Hotel,
London

Life Sciences IP Minds 2017

75+ experts, 10+ countries , 2 information-packed days

Solve the challenges facing the life sciences industry and transform your IP strategy to thrive during a time of uncertainty and change.

Examine the key challenges facing the life sciences industry and prepare your IP for the future

First-hand update on the UPC
  • Hear from Kevin Mooney, the only UK-based lawyer in the Expert Group advising the UPC
  • Discuss the key benefits of opting in or out of the unified patent with an in-house panel
  • Learn about the ramifications the UPC will have on the SPC model
  • Explore the recent CJEU referrals and what they mean for the SPC
Thrive in an uncertain political climate
  • Renowned IP litigator Ken Adamo of Kirkland & Ellis LLP to provide a practical understanding of the latest case law and regulation
  • Explore how recent and pending Supreme Court judgements will affect IP filing and delivery
  • A pan-European discussion on preparing your IP for entry in post-Brexit Britain
  • Discuss what is in store for the EMA and how to minimise impact on IP approval
Stay ahead of the competition with your biological patent strategy
  • Ensure your IP is defensible and robust by understanding the shifting landscape presented by the EPO and EU Commission
  • Formulate a winning IP litigation strategy with top barristers and legal minds
  • Get the latest news from the European Commission on biotech diagnostic testing.
  • Keep your patents global by learning from the BPCIA patent dance and litigation pathway

Key market access strategies for commercially focused IP
  • Overcome the barriers to market access for biosimilar and biobetter products
  • Find out the latest regarding Pregabalin and its disruptive effect on the second medical use patent
  • Discover how the EU Commission and FDA proposals to change orphan drug classification will change your IP strategy
  • Hear from experts involved in the Accelerated Access Review on how to shift your IP timetable to maximise patent lifespan.
Staying compliant with regulations and authorities
  • Unravel the requirements needed to ensure your IP is a success
  • Learn to balance sufficiency and speed
  • Explore the pricing pitfalls to consider as an IP practitioner with a focus on the record Pfizer fine
  • Uncover the complex relationship between transparency/patient rights and your rights as a patent holder
Network with top IP Minds

Representatives from more than a dozen countries will gather to share their insight and knowledge with the Life Sciences IP community. You will have a chance to discuss the latest issues affecting you and your team through Q+A sessions, networking lunches and a relaxed drinks reception.

Sponsorship Opportunities